Search
for
Sort by
Research
810-840 / 1000+ resultsresearch Minoxidil
research Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
research Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
JAK inhibitors show promise for treating alopecia areata but have serious side effects.
research Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
research Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib
Sorafenib often causes skin side effects, indicating effective cancer treatment.
research Oral isotretinoin combined with topical clobetasol 0.05% and tacrolimus 0.1% for the treatment of frontal fibrosing alopecia: a randomized controlled trial
Taking oral isotretinoin with creams worked better for treating a type of hair loss than creams alone.
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research Safety, tolerability, and PK of topical calcitriol formulation for treatment of chemotherapy-induced alopecia (CIA) in patients receiving taxane-based regimen: Final results.
Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
research Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
research 688 Efficacy of topical Vorinostat in the reversal of alopecia areata
Topical Vorinostat shows promise for treating alopecia areata by promoting hair regrowth.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Subacute cutaneous lupus erythematosus presenting as erythroderma
A woman with subacute cutaneous lupus erythematosus had widespread skin symptoms triggered by medication and sunlight, which improved with specific treatments.
research Therapies
The document concludes that low-dose acne treatment is most suitable for moderate acne, with high patient satisfaction and low relapse rates.
research Symmetrical drug‐related intertriginous and flexural exanthema like eruption associated with COVID‐19 vaccination
A skin rash after the AstraZeneca COVID-19 vaccine was treated successfully with medication.
research ANTI-ACNE ACTIVITY OF LIPIDO-STEROLIC EXTRACT OF SERENOA REPENS AND HYDRO-ALCOHOLIC EXTRACT OF GLYCYRRHIZA GLABRA IN SYRIAN HAMSTER EAR MODEL
Liquorice extract may help treat acne by reducing sebum production.
research Melasma, a photoaging disorder
Melasma is now considered a skin aging disorder caused by sun exposure in people with a genetic tendency, which impacts treatment and prevention approaches.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.
research Nanospanlastic vesicles as novel strategies for enhancing anti-glaucoma drug bioavailability
Nanospanlastic vesicles can improve glaucoma treatment by enhancing drug delivery to the eye.
research Intralesional Injection of Triamcinolone Acetonide, Methotrexate and Vitamin D in Treatment of Alopecia Areata: A Narrative Review
Methotrexate and vitamin D3 are potentially more effective and safer than triamcinolone for treating localized alopecia areata.
research Intralesional Methotrexate Is Comparable to Triamicinolone Acetonide and Superior to Vitamin D3 in the Treatment of Alopecia Areata
Intralesional methotrexate and triamcinolone acetonide are more effective than Vitamin D3 for treating alopecia areata.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Novel investigational drugs for alopecia areata and future perspectives
JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
Ixekizumab has known and some unexpected side effects.
research Cutaneous Toxicities From Transplantation-Related Medications
Skin problems from transplant drugs are common and need careful management in organ transplant patients.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Finasteride/Minoxidil
research Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
research Sinus Node Dysfunction in a Child After Developed by the Use of Topical Minoxidil
Topical minoxidil can cause serious heart issues in children.